✦ LIBER ✦

Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes

✍ Scribed by Ana M. Wägner; Jordi Ordóñez-Llanos; Oscar Jorba; Antonio Pérez

Book ID: 116746924
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 43 KB
Volume: 53
Category: Article
ISSN: 1532-8600
DOI: 10.1016/j.metabol.2004.07.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fenofibrate lowers serum triglycerides a

Fenofibrate lowers serum triglycerides and increases low density lipoprotein size in patients with type 2 diabetes

✍ Vakkilainen, J.; Steiner, G.; Ansquer, J.-C.; Taskinen, M.-R. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 164 KB

Change in very low-, low-, and high-dens

Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia

✍ DOV GAVISH; YITZCHAK OSCHRY; MENAHEN FAINARU; SHLOMO EISENBERG 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 709 KB

Effects of cholesterol-lowering treatmen

Effects of cholesterol-lowering treatments on oxidative modification of plasma intermediate density lipoprotein plus low density lipoprotein fraction in Type 2 diabetic patients

✍ Natsuki Harada; Atsunori Kashiwagi; Yoshihiko Nishio; Ryuichi Kikkawa 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 109 KB

Effect of improving glycemic control on

Effect of improving glycemic control on low-density lipoprotein particle size in type 2 diabetes

✍ Ana Marı́a Wägner; Oscar Jorba; Mercedes Rigla; Rosa Bonet; Alberto de Leiva; Jo 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Alterations of lipids and apolipoprotein

Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes

✍ Anne Hiukka; Jamila Fruchart-Najib; Eeva Leinonen; Hannele Hilden; Jean-Charles 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 159 KB

Gemfibrozil treatment increases low-dens

Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alterin vitro oxidizability

✍ O’Neal, D.N.; O’Brien, R.C.; Timmins, K.L.; Grieve, G.D.; Lau, K.P.; Nicholson, 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

The aim of this study was to determine the effect of the lipid modifying agent gemfibrozil on lipid and coagulation risk factors in patients with Type 2 diabetes mellitus (Type 2 DM). Twenty-six subjects with Type 2 DM and dyslipidaemia were treated for 24 weeks with either gemfibrozil 600 mg orally